VEGFA and gastric cancer: Ramucirumab is a monoclonal antibody that targets VEGFR2 to inhibit VEGF-stimulated receptor phosphorylation and downstream signaling (145), and it has been used as various lines of treatment for GC, CRC, NSCLC, and HCC (146).